Radioimmunotherapy of orthotopically transplanted pancreatic cancer with 131I-labeled chimeric monoclonal antibody Nd2

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 179-184

  Yamamoto, Atsushi ^a   Sawada, Tetsuji ^a   Yamashita, Yoshito ^a   Nishihara, Tamahiro ^a   Ho, Jenny J L ^b   Kim, Young Sik ^b   Chung, Kosei Hirakawa Yong Suk ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chimeric Nd2; Orthotopic transplant model; Pancreatic cancer; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; CANCER ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; DRUG SCREENING; FEMALE; HUMAN; MOUSE; NUDE MOUSE; PANCREAS TUMOR; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0032616209     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.1.179     Document Type: Article

References (34)

1. Ho JJL, Bi N, Yan P, Yuan M. Norton KA and Kim YS: Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin. Cancer Res 51: 372-380, 1991.
2. 111In-labeled monoclonal antibody Nd2. Antibody Immunoconj Radiophar 4: 493-499, 1991.
3. 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer. Jpn J Cancer Res 88: 427-434, 1997.
4. 131I-labeled monoclonal antibody Nd2 in xenografted nude mice. Jpn J Cancer Res 87: 977-984, 1996.
5. Gold DV, Alisauskas R and Sharkey RM: Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM-4. Cancer Res 55: 1105-1110, 1995.
6. Kondo Y, Chung YS, Sawada T, Inui A, Yamashita Y, Hirayama K, Nakata B, Ho JJL, Kim YS and Sowa M: Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts. Jpn J Cancer Res 86: 1072-1079, 1995.
7. Reynolds J. Del Vecchino S, Sakahara H, Lora ME, Carrasquillo JA and Neumann RD: Anti-murine antibody response to monoclonal antibodies: clinical findings and implications. Nucl Med Biol 16: 167-170, 1989.
8. Khazaeh MB, Saleh MN, Wheeler RH, Huster WJ, Holden H and Carrano R. Phase-I trial of multiple doses of murine monoclonal antibody CO 17-1 A: Pharmacokinetics and immune response: J Natl Cancer Inst 80: 937-942, 1988.
9. Courtenary-Luck NS, Epenetos AA, Moore R. Larche M. Pectasides D and Dhokia B: Development of primary or secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms: Cancer Res 46: 6489-6493, 1986.
10. Hirayama K, Chung YS, Sawada T, Kim YS and Sowa M: Characterization and biodistribution of a mouse/human chimeric antibody directed against pancreatic cancer mucin. Cancer 75: 1545-1553, 1995.
11. Haisma HJ, Hilgers J and Zurawski VR. Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. J Nucl Med 27: 1890-1895, 1986.
12. 131I-labeled monoclonal antibody CC49. Cancer Res 55 (Suppl): 5881s-5887s, 1995.
13. Jerry AP, Edward WB and Roberto LC: Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (Breast MUC-1 mucin) in breast carcinomas. Cancer Res 57: 1103-1108, 1997.
14. 90Y-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 48: 3270-3275, 1988.
15. Kamigaki T, Yamamoto M. Ohyanagi H, Ohya M. Shimazoe T, Kono A, Ohtani W, Narita Y, Ohkubo M and Saitoh Y: Therapy and imaging of pancreatic carcinoma xenografts with radio-labeled chimeric monoclonal antibody A10 and its Fab fragment. Jpn J Cancer Res 86: 1216-1223, 1995.
16. 131I-chimeric mouse/human B72.3 (human γ 4) monoclonal antibody in humans. Cancer Res 51: 5461-5466, 1991.
17. Kitamura K, Takahashi T, Yamaguchi T, Niguchi A, Noguchi A, Takashina K, Turumi H, Inagake M, Toyokuni T and Hakomori S: Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy. Cancer Res 51: 4310-4315, 1991.
18. Gluec SA, Serafini AN, Moffat FL, Vargas-Cuba RD, Sfakianakis GN, Franceschi D, Crichton VZ, Subramanian R, Klein JL and De Jager RL: Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 55 (Suppl): 5774s-5776s, 1995.
19. 131I-labelled anti-NCAM monoclonal antibody 123C3. Cancer Immunol Immunother 41: 169-174, 1995.
20. Shih LB, Xuan H, Aninipot R. Stein R and Goldenberg DM: In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res 55 (Suppl. 23): 5857S-5863S, 1995.
21. 131-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 47: 5672-5677, 1987.
22. 131I-labeled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer 41: 127-134, 1988.
23. Esteban JM, Schlom J, Mornex F and Colcher D: Radio-immunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 23: 643-655, 1987.
24. Kievit E, Pinedo HM, Schluper HM, Haisma HJ and Boven E: Comparison of monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radio-immunotherapy in human ovarian cancer xenografts. Br J Cancer 73: 457-464, 1996.
25. Alisauskus R, Wong GYC and Gold DV: Initial studies of monoclonal antidody PAM-4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res 55 (Suppl.): 5743s-5748s, 1995.
26. Tan MH and Chu TM: Characterization of the tumorigenic and metastatic properties of a human pancreatic cell line (ASPC-1) implanted orthotopically into nude mice. Tumour Biol 6: 89-98, 1985.
27. Marincola F, Taylor-Edwards C, Drucker B and Holder WD. Orthotopic and heterotopic xenotransplantation of human pancreatic cancer in nude mice. Current Surg 44: 294-297. 1987.
28. Vezeridis MP, Doremus CM, Tibbetts LM, Tzanakakis G and Jackson BT: Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse. J Surg Oncol 40: 261-265, 1989.
29. Furukawa T, Kubota T, Watanabe M, Kitajima M and Huffman RM: A novel 'patient-like' treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. Cancer Res 53: 3070-3072, 1993.
30. Togo S, Shimada H, Kubota T, Moosa A R and Huffman M: Host organ specifically determines cancer progression. Cancer Res 55: 681-684, 1995.
31. Shitara K, Kuwana Y, Nakamura K, Tokutake Y, Ohta S, Miyaji H, Hasegawa M and Hanai N: A mouse human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities. Cancer Immunol Immunother 36: 373-380, 1993.
32. Koga H, Kanda H, Nakashima M, Watanabe Y, Endo K and Watanabe T: Mouse-human chimeric monoclonal antibody to carcinoembryonic antigen (CEA): in vitro and in vivo activities. Hybridoma 9: 43-56, 1990.
33. Liu AY, Robinson RR, Hellstrom KE, Murray ED, Chang CP Jr and Hellstrom I: Chimeric mouse-human IgGI antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA 84: 3439-3443, 1987.
34. Gallinger S, Papa MZ, Reilly RM, Xiang J, Kirsh JC, Mullen JBM, Stern HS, Hozumi N and Roder JC: Comparative biodistribution and antibody-dependent cellular cytotoxicity of native and heavy chain chimeric antibody. Mol Biother 3: 197-203, 1991.